ClinicalTrials.govpublic full text
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
renal cell carcinoma, clear cell, somatic, fruquintinib, everolimus, interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1045475
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.